Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
NEW YORK, Dec. 23, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of California on behalf of investors who purchased Illumina, Inc. (NASDAQ:ILMN) securities between July 26, 2016 and October 10, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/illumina-inc-ilmn. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, Defendants failed to disclose that: (1) Illumina was suffering a large decline in its instrument sales; (2) this decline was damaging Illumina’s revenue; (3) Illumina lacked visibility into trends that could have a substantial impact on its financial results; (4) as such, Illumina’s revenue guidance was unreliable and overstated; and (5) consequently, Illumina’s statements concerning its business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
On October 10, 2016 Illumina announced disappointing financial results for the third quarter of fiscal year 2016. The company had predicted revenues of $625 to $630 million for the quarter. However, citing “declining demand for its high-speed genetic sequences,” Illumina generated just $607 million. Following this news, Illumina stock dropped as much as 25% during intraday trading on October 11, 2016.
If you suffered a loss in Illumina you have until February 14, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/illumina-inc-ilmn.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
